C. Jandus

Discipline

Histoire, Philosophie et Sociologie des sciences (5) Linguistique (1) Sciences de l'information et de la communication (1) Economies et finances (1)

Type de document

Articles (32) Recensions (6)

Co-auteur

Date

Source

Mot-clé

Cells (22) T cells (19) Human beings (18) Patients (15) Cancer (15) Patients (15) cancer (14) Cancer (14) Immunotherapy (12) Expression (12) Immunotherapy (12) Lymphocytes (9) Treatment (8) Phenotype (8) Tumors (8) Functions (8) immunité (7) Diseases (7) Immunity (7) Diseases (7) Animals (7) Tumors (7) spectacle (6) Vaccination (6) Mice (6) Vaccination (6) roman (6) thérapie (5) protéine (5) ligne (5)

Documents écrit par C. Jandus (32) | parle de C. Jandus (0)

Static Adhesion Assay for Human Peripheral Blood Mononuclear Cells.
G. Vanoni et al. (5 janv. 2022)
Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer.
M. Calvi et al. (2022)
c-Met enforces proinflammatory and migratory features of human activated CD4+ T cells.
M. Benkhoucha et al.
PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.
G. Ercolano et al. (5 mai 2021)
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer.
M. Saillard et al. (4 mai 2021)
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
A. Cachot et al.
Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment.
A. Gomez-Cadena et al.
Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer.
H. El Ahanidi et al. (2021)
Editorial: Memory T Cells in Chronic Infections and Tumors.
M. Hofmann et al. (2021)
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes.
S. Pesce et al. (25 nov. 2020)
Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment.
A. Gomez-Cadena et al. (18 mai 2020)
Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus.
R. Lande et al. (3 avr. 2020)
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
H. Wang et al.
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
B. Salomé et al. (26 nov. 2019)
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.
B. Mastelic-Gavillet et al. (10 oct. 2019)
Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development.
C. Guay et al. (5 févr. 2019)
ILC2s: New Actors in Tumor Immunity.
G. Ercolano et al. (2019)
Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints.
N. Gourdin et al. (1 juil. 2018)
Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping.
S. Trabanelli et al.
Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.
C. Kowalczyk-Quintas et al. (2018)
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
M.F. Chevalier et al. (2017)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
P. Baumgaertner et al. (2016)
Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells.
G. Scholz et al. (2016)
NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions.
K. Ludigs et al. (2016)
CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.
S. Trabanelli et al. (2015)

next